International Journal of Clinical Medicine

Volume 5, Issue 14 (July 2014)

ISSN Print: 2158-284X   ISSN Online: 2158-2882

Google-based Impact Factor: 0.51  Citations  

Long Term Outcome of Bisphosphonate Therapy in Patients with Primary Hyperparathyroidism

HTML  XML Download Download as PDF (Size: 953KB)  PP. 829-835  
DOI: 10.4236/ijcm.2014.514111    3,067 Downloads   4,303 Views  Citations

ABSTRACT

Context: Primary hyperparathyroidism (PHPT) is commonly associated with reduced bone mineral density (BMD) presenting with osteoporosis, increasing the risk of bone fragility fractures in these patients. Bisphosphonates, due to their anti-resorptive action, are known to improve the BMD and reduce the risk of bone fragility fractures. Therefore, bisphosphonates are considered as an alternative to surgical treatment in managing osteoporosis in PHPT patients. Aim: The aim of this observational study was to assess the effect of long term bisphosphonate therapy on BMD, bone fragility fracture and biochemical markers of bone metabolism in patients with PHPT. Methodology: Fifty patients (mean age 74 years) with PHPT who were treated with long term bisphosphonate therapy were studied retrospectively. The mean baseline (before commencing bisphosphonate therapy) BMD T-scores for lumbar spine (L2-L4) and left femoral neck were -2.5 and -2.1, respectively. Fourteen patients had bone fragility fractures before initiation of bisphosphonate therapy. Results: After an average of 5 years of bisphosphonate treatment, there was a significant increase in lumbar BMD T-score (-2.5 to -2.1, p = 0.013) and a non-significant change in left femoral neck BMD T-score (-2.1 to -2.2, p = 0.497). There was no increase in bone fragility fracture rate (p = 0.167). Serum corrected calcium reduced from 2.74 mmol/L to 2.60 mmol/L (p < 0.001) and urine calcium to creatinine ratio from 0.70 to 0.55 (p < 0.0001), both within the reference range. Conclusions: Our study suggests that long term bisphosphonate therapy improves lumbar BMD and prevents increase in bone fragility fracture rate. Additionally it improves hypercalcaemia in PHPT.

Share and Cite:

Segula, D. , Nikolova, T. , Marks, E. , Ranganath, L. and Mishra, V. (2014) Long Term Outcome of Bisphosphonate Therapy in Patients with Primary Hyperparathyroidism. International Journal of Clinical Medicine, 5, 829-835. doi: 10.4236/ijcm.2014.514111.

Cited by

[1] Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients
Endocrine …, 2023
[2] Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic …
Frontiers in …, 2023
[3] Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency
Endocrine, 2023
[4] Проект клинических рекомендаций по диагностике и лечению первичного гиперпаратиреоза у взрослых пациентов
Эндокринная …, 2022
[5] Denosumab for Osteoporosis in Patients With Primary Hyperparathyroidism and Renal Insufficiency
2022
[6] Клинические рекомендации по первичному гиперпаратиреозу, краткая версия
Проблемы …, 2021
[7] The clinical practice guidelines for primary hyperparathyroidism, short version
Problems of …, 2021
[8] INSTITUTO UNIVERSITÁRIO EGAS MONIZ
2019
[9] Skeletal Manifestations of Hyperparathyroidism
2018
[10] Prevalência do tipo de rebordo alveolar nos desdentados da consulta de reabilitação oral I e II da clínica universitária Egas Moniz
2018
[11] Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
Frontiers in endocrinology, 2017
[12] Estratégias para a preservação do rebordo alveolar
2016
[13] INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE
2015

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.